Swiss biotech partnership brings Mitopure® to skincare, clinically proven to energize cellular mitochondria.
Biotech powers Lancôme innovation
Lancôme centers
skin longevity science in its strategy. In addition, partners with Swiss biotech
Timeline®, pioneer of Mitopure®, activating skin cell mitophagy. Backed by
$50M+ R&D, Mitopure® is pure Urolithin A. Thus, it restores mitochondrial energy, targeting visible biological skin aging.
Proactive skincare era dawns
L’Oréal Group led beauty into longevity investing in Timeline® 2024. Now Lancôme launches Mitopure®-infused line with proprietary actives, industry benchmark. “Longevity is radical progress, beyond looks. We redefine aging with cutting-edge science,” states
Vania Lacascade, Lancôme Global President. Meanwhile, biotech democratizes cellular benefits.
Longevity ecosystem expands
Integrates
Absolue Longevity The Soft Cream with Absolue PDRN™ and
Cell BioPrint™ via NanoEnTek proteomics. In turn, shifts reactive correction to data-driven prediction. Mitopure® line debuts at
AAD convention, March 2026. Thus, holistic science preserves skin “healthspan” comprehensively.
About Timeline® and Lancôme
Timeline® advances cellular health with 15 years research,
50 patents. Nestlé Health Science and L’Oréal backed, extends Mitopure® to global skincare. Founded
1935,
Lancôme blends science, emotion empowering women. In Brazil, premium portfolio emphasizes sustainable innovation, vitality.
